Available Technology

Antagonist of A3 Adenosine Receptor Fluorescent Probes for the Study of Diseases that Involve A3 Signaling

This molecular probe may serve as a companion tool to identify and stratify patient populations based on the prevalence of the target A3adenosine receptors.
Patent Abstract: 
This molecular probe may serve as a companion tool to identify and stratify patient populations based on the prevalence of the target A3adenosine receptors. Small molecule drugs, A3AR-selective agonists, are currently in advanced clinical trials for the treatment of hepatocellular carcinoma, autoimmune inflammatory diseases, such as rheumatoid arthritis, psoriasis, and dry eye disease, and other conditions.
Benefits 
Avoids the use of radioisotopes in this part of the R&D process.
applications 
Inventors: 
Kenneth Jacobson
Patent Number: 
13/748,826 (Note: a separate license may be requir
Internal Laboratory Ref #: 
E-073-2012/0
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin